GAMMA Investing LLC raised its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9,296.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,175 shares of the biopharmaceutical company's stock after buying an additional 8,088 shares during the quarter. GAMMA Investing LLC's holdings in Agios Pharmaceuticals were worth $240,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in AGIO. Jefferies Financial Group Inc. purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $49,290,000. Adage Capital Partners GP L.L.C. purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $9,957,000. Paradigm Biocapital Advisors LP purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $9,084,000. Deutsche Bank AG grew its holdings in Agios Pharmaceuticals by 39.7% in the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after buying an additional 265,637 shares in the last quarter. Finally, Casdin Capital LLC purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $8,215,000.
Agios Pharmaceuticals Price Performance
Shares of Agios Pharmaceuticals stock opened at $34.41 on Friday. The business has a 50-day moving average of $30.69 and a 200 day moving average of $32.75. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of 3.06 and a beta of 0.73.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, Scotiabank lowered their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $58.60.
Check Out Our Latest Research Report on Agios Pharmaceuticals
Insider Activity at Agios Pharmaceuticals
In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.
Agios Pharmaceuticals Company Profile
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
